RAPT Therapeutics, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €15.48M +∞% -€207.52M +31.6% -1,340.5% -13 pp N/A N/A
    (estimated) €0.00 +NaN% -€157.67M +36.5% N/A N/A N/A
    (estimated) €0.00 +NaN% -€115.55M +32.2% N/A N/A N/A
    (estimated) €0.00 +NaN% -€87.43M +27.3% N/A -€44.75M +0.0% N/A
    (estimated) €0.00 +NaN% -€68.69M -38.0% N/A -€44.75M -36.9% N/A
    €0.00 +NaN% -€110.77M +11.2% N/A -€70.94M -13.3% N/A
    €0.00 -100.0% -€99.62M +42.6% N/A -€81.82M +37.2% N/A
    €1.30M -60.0% -€69.84M +20.0% -5,362.2% -36 pp -€59.64M +16.0% -4,579.3% -30 pp
    €3.25M -24.4% -€58.18M +29.0% -1,788.8% -7.4 pp -€51.41M +50.3% -1,580.7% -7.9 pp
    €4.30M +∞% -€45.11M +23.0% -1,049.0% -10 pp -€34.20M +15.9% -795.2% -8.0 pp
    €0.00 +NaN% -€36.67M +19.0% N/A -€29.50M +17.4% N/A
    €0.00 +NaN% -€30.83M +24.2% N/A -€25.12M +13.3% N/A
    €0.00 -€24.83M N/A -€22.18M N/A

    Notifications